**Core Concept**
The question pertains to the immunophenotypic characteristics of Acute Lymphoblastic Leukemia (ALL), specifically the cell surface markers expressed by the malignant lymphoid cells. **Acute Lymphoblastic Leukemia (ALL)** is a type of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells.

**Why the Correct Answer is Right**
Although the specific correct answer choice is not provided, typically, most ALLs express **CD10 (Common Acute Lymphoblastic Leukemia Antigen)** and **CD19**, among other markers. The expression of these markers is crucial for the diagnosis and subclassification of ALL.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific details of option A, it's challenging to provide a precise explanation for its incorrectness.
**Option B:** Similarly, without knowing what option B entails, we cannot accurately describe why it is incorrect.
**Option C:** Assuming option C might represent an incorrect or less common marker for ALL, it would be incorrect because it does not accurately reflect the most common immunophenotypic profile of ALL cells.
**Option D:** This option would also be incorrect for similar reasons, assuming it does not align with the typical markers expressed by ALL cells.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that the immunophenotyping of ALL is critical for its diagnosis and management. **CD10** and **CD19** are among the markers commonly used to diagnose and monitor ALL.

**Correct Answer:** Correct Answer: D. CD10